Previous Close | 2.6000 |
Open | 2.5700 |
Bid | 2.7900 x 1300 |
Ask | 2.7900 x 1800 |
Day's Range | 2.5000 - 2.5800 |
52 Week Range | 0.9200 - 3.7900 |
Volume | |
Avg. Volume | 4,730,530 |
Market Cap | 620.517M |
Beta (5Y Monthly) | 1.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.7700 |
Earnings Date | Apr 30, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for LXRX
New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
THE WOODLANDS, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients with type 1 diabetes and chronic kidney disease (CKD). In this important patient population, treatment with sotagliflozin successfully lowered A1C, body weight, and systolic blood pressure with safety similar t
Lexicon (LXRX) delivered earnings and revenue surprises of 13.04% and 3.24%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?